Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modulating paclitaxel bioavailability for targeting prostate cancer.

Srinivas K Kumar1, Simon A Williams, John T Isaacs

  • 1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA.

Bioorganic & Medicinal Chemistry
|May 16, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Castration Resistance Accelerates Prostate Cancer Kinetics.

The Prostate·2026
Same author

WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.

European urology oncology·2026
Same author

Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing Testing.

JCO oncology practice·2026
Same author

Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer.

Cancer research·2025
Same author

Apoptosis, ferroptosis, necrosis, necroptosis and pyroptosis in the formation of calcium oxalate kidney stones.

Urolithiasis·2025
Same author

Oxidative stress, inflammation and kidney stones.

Urolithiasis·2025

Novel peptide-paclitaxel prodrugs activated by prostate-specific antigen (PSA) show promise for prostate cancer therapy. Ethylene diamine linkers enhanced prodrug stability and PSA-mediated drug release, leading to targeted cancer cell death.

Area of Science:

  • Medicinal Chemistry
  • Drug Delivery
  • Oncology

Background:

  • Prostate cancer therapy requires targeted drug delivery to minimize systemic toxicity.
  • Prostate-specific antigen (PSA) is a biomarker overexpressed in prostate cancer, making it a target for prodrug activation.
  • Paclitaxel is a potent chemotherapeutic agent with broad-spectrum activity.

Purpose of the Study:

  • To design and synthesize novel PSA-activated peptide-paclitaxel prodrugs for targeted prostate cancer treatment.
  • To evaluate the stability, PSA-mediated activation, and cytotoxicity of these prodrugs.
  • To identify optimal linker strategies for enhanced prodrug performance.

Main Methods:

  • Synthesis of four peptide-paclitaxel conjugates utilizing PSA-cleavable peptides (HSSKLQ, SSKYQ) and self-immolative linkers (PABS, EDA).

Related Experiment Videos

  • Assessment of prodrug stability in serum-containing media.
  • Evaluation of PSA-mediated hydrolysis and drug release kinetics.
  • Cytotoxicity assays against various cell lines, including PSA-secreting CWR22Rv1 cells.

    • Main Results:

    • Prodrugs with ethylene diamine (EDA) linkers demonstrated improved stability and efficient PSA-mediated activation compared to those with para-aminobenzyl alcohol (PABS) linkers.
    • Prodrug 5, featuring an EDA linker, exhibited stability and effective conversion to active paclitaxel in the presence of PSA.
    • Cytotoxicity studies confirmed targeted cell killing in PSA-expressing cancer cells.

    Conclusions:

    • Ethylene diamine linkers enhance the stability and PSA-specific activation of peptide-paclitaxel prodrugs.
    • Prodrug 5 represents a promising candidate for prostate cancer-specific therapy due to its targeted activation and potent cytotoxicity.
    • These findings support the development of PSA-cleavable prodrugs for improved prostate cancer treatment strategies.